LaFleur & Godfrey LLC Sells 12,776 Shares of Hologic, Inc. (NASDAQ:HOLX)

LaFleur & Godfrey LLC lessened its position in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 9.8% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 117,597 shares of the medical equipment provider's stock after selling 12,776 shares during the period. LaFleur & Godfrey LLC owned approximately 0.05% of Hologic worth $7,264,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Principal Financial Group Inc. lifted its stake in Hologic by 0.6% during the fourth quarter. Principal Financial Group Inc. now owns 271,152 shares of the medical equipment provider's stock valued at $19,547,000 after purchasing an additional 1,606 shares during the last quarter. Venturi Wealth Management LLC lifted its position in shares of Hologic by 156.3% during the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock valued at $31,000 after acquiring an additional 261 shares during the last quarter. Global Retirement Partners LLC lifted its position in shares of Hologic by 15.5% during the 4th quarter. Global Retirement Partners LLC now owns 2,175 shares of the medical equipment provider's stock valued at $157,000 after acquiring an additional 292 shares during the last quarter. Private Advisor Group LLC boosted its stake in shares of Hologic by 7.7% during the 4th quarter. Private Advisor Group LLC now owns 17,931 shares of the medical equipment provider's stock worth $1,293,000 after acquiring an additional 1,278 shares in the last quarter. Finally, RWC Asset Management LLP grew its holdings in shares of Hologic by 13.0% in the 4th quarter. RWC Asset Management LLP now owns 2,971 shares of the medical equipment provider's stock worth $214,000 after acquiring an additional 342 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on HOLX. Wall Street Zen downgraded Hologic from a "buy" rating to a "hold" rating in a report on Monday, May 5th. Morgan Stanley reduced their price objective on shares of Hologic from $77.00 to $65.00 and set an "equal weight" rating for the company in a research note on Monday, May 5th. Argus cut shares of Hologic from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Stephens cut their price target on shares of Hologic from $77.00 to $70.00 and set an "overweight" rating on the stock in a report on Tuesday, May 13th. Finally, Evercore ISI reduced their price target on shares of Hologic from $65.00 to $62.00 and set an "in-line" rating for the company in a research report on Friday, May 2nd. Twelve research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $77.42.

Insider Activity

In other Hologic news, Director Martin D. Madaus purchased 5,445 shares of the business's stock in a transaction dated Wednesday, May 7th. The shares were acquired at an average price of $55.24 per share, for a total transaction of $300,781.80. Following the acquisition, the director now owns 5,445 shares of the company's stock, valued at $300,781.80. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 1.88% of the stock is owned by corporate insiders.

Hologic Stock Down 0.9%

HOLX stock traded down $0.56 during midday trading on Wednesday, reaching $64.27. The company had a trading volume of 2,015,098 shares, compared to its average volume of 2,356,501. The company has a 50 day moving average of $59.55 and a two-hundred day moving average of $64.21. The company has a market capitalization of $14.32 billion, a P/E ratio of 27.12, a PEG ratio of 2.36 and a beta of 0.55. Hologic, Inc. has a 1 year low of $51.90 and a 1 year high of $84.67. The company has a current ratio of 3.24, a quick ratio of 2.52 and a debt-to-equity ratio of 0.54.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. Hologic had a net margin of 13.83% and a return on equity of 19.71%. Hologic's revenue for the quarter was down 1.2% compared to the same quarter last year. During the same period in the prior year, the business posted $1.03 earnings per share. On average, equities research analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.